The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zügel, U.
Right arrow Articles by Grey, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zügel, U.
Right arrow Articles by Grey, H. M.
The Journal of Immunology, 1998, 161: 1705-1709.
Copyright © 1998 by The American Association of Immunologists

Termination of Peripheral Tolerance to a T Cell Epitope by Heteroclitic Antigen Analogues1

Ulrich Zügel*, Rongfang Wang*, Grace Shih*, Alessandro Sette{dagger}, Jeff Alexander{dagger} and Howard M. Grey2,*

* La Jolla Institute for Allergy and Immunology, San Diego, CA 92121; and {dagger} Cytel Corporation, San Diego, CA 92121

Treating mice with an immunodominant T cell epitope from moth cytochrome c (MCC88–103) can induce T cell unresponsiveness under certain conditions of administration. In this report, we determined whether T cell tolerance to MCC88–103 in adult animals can be overcome by immunization with cross-reactive analogues of the tolerizing Ag. A panel of analogues of the tolerogen were tested for their capacity to terminate the tolerant state following in vivo immunization. As analyzed by their stimulatory capacity for a representative MCC88–103-specific T cell clone, this panel covered a wide range of cross-reactivity, including nonantigenic, antagonistic, weakly, and strongly antigenic peptides. Interestingly, only heteroclitic analogues, as measured in vitro by their enhanced antigenicity for the T cell clone that was specific for MCC88–103, were capable of breaking tolerance. Thus, an immune response to the cross-reactive, heteroclitic analogues of tolerized self Ags may represent a mechanism by which Ag molecular mimicry operates.




This article has been cited by other articles:


Home page
J. Immunol.Home page
J. Lustgarten, A. L. Dominguez, and C. Pinilla
Identification of Cross-Reactive Peptides Using Combinatorial Libraries Circumvents Tolerance against Her-2/neu-Immunodominant Epitope
J. Immunol., February 1, 2006; 176(3): 1796 - 1805.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Z. Illes, H. Waldner, J. Reddy, E. Bettelli, L. B. Nicholson, and V. K. Kuchroo
T Cell Tolerance Induced by Cross-Reactive TCR Ligands Can Be Broken by Superagonist Resulting in Anti-Inflammatory T Cell Cytokine Production
J. Immunol., August 1, 2005; 175(3): 1491 - 1497.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
Q. Lou, R. J. Kelleher Jr, A. Sette, J. Loyall, S. Southwood, R. B. Bankert, and S. H. Bernstein
Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells
Blood, August 1, 2004; 104(3): 752 - 759.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. W. J. Schreurs, K. B. J. Scholten, E. W. M. Kueter, J. J. Ruizendaal, C. J. L. M. Meijer, and E. Hooijberg
In Vitro Generation and Life Span Extension of Human Papillomavirus Type 16-Specific, Healthy Donor-Derived CTL Clones
J. Immunol., September 15, 2003; 171(6): 2912 - 2921.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
K. Kimachi, K. Sugie, and H. M. Grey
Effector T cells have a lower ligand affinity threshold for activation than naive T cells
Int. Immunol., July 1, 2003; 15(7): 885 - 892.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
W. Yang and H. M. Grey
Study of the Mechanism of TCR Antagonism Using Dual-TCR-Expressing T Cells
J. Immunol., May 1, 2003; 170(9): 4532 - 4538.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Castilleja, D. Carter, C. L. Efferson, N. E. Ward, K. Kawano, B. Fisk, A. P. Kudelka, D. M. Gershenson, J. L. Murray, C. A. O'Brian, et al.
Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex
J. Immunol., October 1, 2002; 169(7): 3545 - 3554.
[Abstract] [Full Text] [PDF]


Home page
Mayo Clin Proc.Home page
C. Buteau, S. N. Markovic, and E. Celis
Challenges in the Development of Effective Peptide Vaccines for Cancer
Mayo Clin. Proc., April 1, 2002; 77(4): 339 - 349.
[Abstract] [PDF]


Home page
J. Immunol.Home page
D. A. Ostrov, M. M. Roden, W. Shi, E. Palmieri, G. J. Christianson, L. Mendoza, G. Villaflor, D. Tilley, N. Shastri, H. Grey, et al.
How H13 Histocompatibility Peptides Differing by a Single Methyl Group and Lacking Conventional MHC Binding Anchor Motifs Determine Self-Nonself Discrimination
J. Immunol., January 1, 2002; 168(1): 283 - 289.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. E. de Visser, T. A. Cordaro, H. W. H. G. Kessels, F. H. Tirion, T. N. M. Schumacher, and A. M. Kruisbeek
Low-Avidity Self-Specific T Cells Display a Pronounced Expansion Defect That Can Be Overcome by Altered Peptide Ligands
J. Immunol., October 1, 2001; 167(7): 3818 - 3828.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Tangri, G. Y. Ishioka, X. Huang, J. Sidney, S. Southwood, J. Fikes, and A. Sette
Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes that Are More Potent and Immunogenic than Wild-Type Peptide
J. Exp. Med., September 17, 2001; 194(6): 833 - 846.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
PNAS, June 20, 2001; (2001) 141226398.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. K. Joshi, P. R. Suresh, and V. S. Chauhan
Flexibility in MHC and TCR Recognition: Degenerate Specificity at the T Cell Level in the Recognition of Promiscuous Th Epitopes Exhibiting No Primary Sequence Homology
J. Immunol., June 1, 2001; 166(11): 6693 - 6703.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. M. Anderton, C. G. Radu, P. A. Lowrey, E. S. Ward, and D. C. Wraith
Negative Selection during the Peripheral Immune Response to Antigen
J. Exp. Med., December 27, 2000; 193(1): 1 - 12.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Lu and E. Celis
Use of Two Predictive Algorithms of the World Wide Web for the Identification of Tumor-reactive T-Cell Epitopes
Cancer Res., September 1, 2000; 60(18): 5223 - 5227.
[Abstract] [Full Text]


Home page
J. Virol.Home page
L. Bouhdoud, P. Villain, A. Merzouki, M. Arella, and C. Couture
T-Cell Receptor-Mediated Anergy of a Human Immunodeficiency Virus (HIV) gp120-Specific CD4+ Cytotoxic T-Cell Clone, Induced by a Natural HIV Type 1 Variant Peptide
J. Virol., March 1, 2000; 74(5): 2121 - 2130.
[Abstract] [Full Text]


Home page
JEMHome page
R. Wang, Y. Wang-Zhu, C. R. Gabaglia, K. Kimachi, and H. M. Grey
The Stimulation of Low-Affinity, Nontolerized Clones by Heteroclitic Antigen Analogues Causes the Breaking of Tolerance Established to an Immunodominant T Cell Epitope
J. Exp. Med., October 4, 1999; 190(7): 983 - 994.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
L. Fong, Y. Hou, A. Rivas, C. Benike, A. Yuen, G. A. Fisher, M. M. Davis, and E. G. Engleman
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
PNAS, July 17, 2001; 98(15): 8809 - 8814.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1998 by The American Association of Immunologists, Inc. All rights reserved.